SLC5A2 and fatty liver disease: Several previous studies reported that canagliflozin [19], dapagliflozin [20], and empagliflozin [21], irrespective of SGLT-2 selectivity, have a beneficial effect on hepatic steatosis or fibrosis in T2DM patients with NAFLD.